Pyridyl reverse sulfonamides for HBV treatment

Patent metadata

Field	Value
Publication number	US-10160742-B2
Application number	US-201715676236-A
Country	US
Kind code	B2
Filing date	Aug 14, 2017
Priority date	Dec 30, 2014
Publication date	Dec 25, 2018
Grant date	Dec 25, 2018

Abstract

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

First claim

The invention claimed is:

1. A compound of Formula II:

or a pharmaceutically acceptable salt thereof;
wherein
one R 1 is H and one R 1 is selected from halo and C 1-6 -alkyl;
R 2 is halo;
R 3 is halo;
R 4 is C 1-6 -heteroalkyl or heteroaryl, each of which may be independently substituted with one or two of C 1-6 -alkyl;
R 5 is H; and
n is 0 or 1.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

3. A composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, further comprising at least one pharmaceutically acceptable carrier.

4. A method of treating an HBV infection in an individual having an HBV infection, comprising administering to the individual a therapeutically effective amount of a compound according to claim 1 .

5. The method of claim 4 , further comprising administering to the individual at least one additional therapeutic agent selected from the group consisting of an HBV vaccine, HBV polymerase inhibitor, interferon, pegylated interferon, viral entry inhibitor, viral maturation inhibitor, BAY 41-4109, reverse transcriptase inhibitor, a TLR-agonist, AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide), and AT-130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)-4-nitrobenzamide), and a combination thereof.

6. The method of claim 5 , wherein the pegylated interferon is pegylated interferon alpha (IFN-α), pegylated interferon lambda (IFN-λ), or pegylated interferon gamma (IFN-γ).

7. The method of claim 5 , wherein the reverse transcriptase inhibitor is at least one of Zidovudine, Didanosine, Zalcitabine, ddA, Stavudine, Lamivudine, Abacavir, Emtricitabine, Entecavir, Apricitabine, Atevirapine, ribavirin, acyclovir, famciclovir, valacyclovir, ganciclovir, valganciclovir, Tenofovir, Adefovir, cidofovir, Efavirenz, Nevirapine, Delavirdine, or Etravirine.

8. The method of claim 5 , wherein the TLR-agonist is selected from the group consisting of SM360320 (9-benzyl-8-hydroxy-2-(2-methoxy-ethoxy)adenine) and AZD 8848 (methyl [3-({[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl][3-(4-morpholinyl)propyl]amino}lmethyl)phenyl]acetate).

Assignees

• Novira Therapeutics Inc

Inventors

• Clark Ryan C
• Truong Yen
• Stock Nicholas
• Jacintho Jason

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07D213/81

  Amides; Imides · CPC title

• C07D231/18

  One oxygen or sulfur atom · CPC title

• C07D333/26 Primary

  with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms · CPC title